Sacred Heart University, 5151 Park Ave, Fairfield, CT, 06825, USA.
Duke Health, Durham, NC, USA.
Int J Clin Pharm. 2021 Apr;43(2):394-403. doi: 10.1007/s11096-020-01216-9. Epub 2021 Jan 18.
Background Duloxetine is currently approved for chronic pain management; however, despite some evidence, its utility in acute, postoperative pain remains unclear Aim of the review This systematic review and meta-analysis is to determine if duloxetine 60 mg given perioperatively, is safe and effective at reducing postoperative opioid consumption and reported pain following elective orthopedic surgery. Method CINAHL, Medline, Cochrane Central Registry for Clinical Trials, Google Scholar, and Clinicaltrials.gov were searched using a predetermined search strategy from inception to January 15, 2019. Covidence.org was used to screen, select, and extract data by two independent reviewers. Individual study bias was assessed using the Cochrane Risk of Bias tool. Opioid consumption data were converted to oral morphine milligram equivalents (MME) and exported to RevMan where meta-analysis was conducted using a DerSimonian and Laird random effects model. Results Six randomized-controlled trials were included in the literature review of postoperative pain and adverse effects. Five studies were utilized for the meta-analysis of postoperative opioid consumption; totaling 314 patients. Postoperative pain analysis showed variable statistical significance with overall lower pain scores with duloxetine. Adverse effects included an increase in insomnia with duloxetine but lower rates of nausea and vomiting. Meta-analysis revealed statistically significant [mean difference (95% CI)] lower total opioid use with duloxetine postoperatively at 24 h [- 31.9 MME (- 54.22 to - 9.6), p = 0.005], 48 h [- 30.90 MME (- 59.66 to - 2.15), p = 0.04] and overall [- 31.68 MME (- 46.62 to - 16.74), p < 0.0001]. Conclusion These results suggest that adding perioperative administration duloxetine 60 mg to a multimodal analgesia regimen within the orthopedic surgery setting significantly lowers total postoperative opioid consumption and reduces pain without significant adverse effects.
度洛西汀目前被批准用于慢性疼痛管理;然而,尽管有一些证据,但它在急性、术后疼痛中的效用仍不清楚。
本系统评价和荟萃分析旨在确定在择期骨科手术中,围手术期给予度洛西汀 60mg 是否安全有效,能否减少术后阿片类药物的消耗和报告的疼痛。
从建库到 2019 年 1 月 15 日,我们使用预先确定的搜索策略,在 CINAHL、Medline、Cochrane 临床试验中心注册库、Google Scholar 和 Clinicaltrials.gov 进行了检索。Covidence.org 用于通过两名独立评审员筛选、选择和提取数据。使用 Cochrane 偏倚风险工具评估个别研究的偏倚。将阿片类药物消耗数据转换为口服吗啡毫克当量(MME),并导出到 RevMan 中,使用 DerSimonian 和 Laird 随机效应模型进行荟萃分析。
在术后疼痛和不良反应的文献综述中,共纳入了 6 项随机对照试验。有 5 项研究用于术后阿片类药物消耗的荟萃分析;共纳入 314 名患者。术后疼痛分析显示,度洛西汀组的疼痛评分总体较低,但存在统计学差异。不良反应包括度洛西汀组失眠发生率增加,但恶心和呕吐发生率较低。荟萃分析显示,度洛西汀组术后 24 小时[-31.9 MME(-54.22 至-9.6),p=0.005]、48 小时[-30.90 MME(-59.66 至-2.15),p=0.04]和总体[-31.68 MME(-46.62 至-16.74),p<0.0001]的总阿片类药物使用量明显较低。
这些结果表明,在骨科手术环境中,将围手术期给予度洛西汀 60mg 加入多模式镇痛方案中,可显著降低术后总阿片类药物消耗,减轻疼痛,且无明显不良反应。